Group 1 - The high-pressure oxygen chamber concept declined by 0.68%, ranking among the top declines in concept sectors as of the market close on August 20 [1] - Within the high-pressure oxygen chamber sector, companies such as Innovate Medical, Yinkang Life, and Aoyang Health experienced significant declines, while Iron Construction Heavy Industry, Samsung Medical, and Dahu Co. saw increases of 4.29%, 1.08%, and 0.89% respectively [1] - The high-pressure oxygen chamber sector experienced a net outflow of 444 million yuan in main funds, with Innovate Medical leading the outflow at 537 million yuan [2] Group 2 - The top gainers in the market included the Tonghuashun Fruit Index at 3.70%, AI mobile phones at 2.77%, and MCU chips at 2.60%, while the high-pressure oxygen chamber concept was among the top decliners [2] - The main funds saw significant outflows from several stocks in the high-pressure oxygen chamber sector, with Innovate Medical, Aoyang Health, and Dahu Co. being the most affected [2] - Conversely, Iron Construction Heavy Industry, Samsung Medical, and Jinling Pharmaceutical attracted net inflows of main funds, indicating a shift in investor interest [2]

Core Viewpoint - Jinling Pharmaceutical's subsidiary, Fuzhou Meifeng Pharmaceutical Factory, has received a re-registration approval notice for hydrolyzed protein injection from the Fujian Provincial Drug Administration, which is expected to facilitate the resumption of production and sales of the drug [1] Group 1: Company Developments - The drug approval notification number is 2025R079210, and the product specification is 500ml:25g (hydrolyzed protein), classified as a chemical drug [1] - The hydrolyzed protein injection is indicated for severe amino acid deficiency and hypoproteinemia [1] - Due to long-term suspension of production, the company must apply for an on-site inspection from the provincial drug administration before resuming production and sales [1] Group 2: Market Impact - The re-registration is beneficial for the drug's production and sales recovery, but it is noted that there will be no significant impact on the company's recent performance [1] - The production and sales of the drug are subject to uncertainties influenced by policies and market factors [1]

金陵药业公告称，公司分公司金陵药业股份有限公司福州梅峰制药厂近日收到福建省药品监督管理局下 发的药品再注册批准通知书。该药品为水解蛋白注射液，主要用于手术严重创伤、大面积烧伤引起的严 重氨基酸缺乏，以及各种疾病引起的低蛋白血症。由于长期未生产，恢复生产时需向省级药品监督管理 部门提出现场检查申请，并经抽取三批产品检验合格后，方可上市销售。该批准通知书将有利于上述药 品恢复正常生产和销售，但不会对公司近期经营业绩产生重大影响。 （文章来源：第一财经） ...

受理号：CYHZ2514512 闽 药品名称：水解蛋白注射液 证券代码：000919 证券简称：金陵药业 公告编号：2025-057 金陵药业股份有限公司 关于分公司收到药品再注册批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 金陵药业股份有限公司（以下简称"公司"）分公司金陵药业股 份有限公司福州梅峰制药厂于近日收到福建省药品监督管理局下发 的药品再注册批准通知书（2025R079210），现将相关情况公告如下： 一、申请注册药品的基本情况 二、水解蛋白注射液的相关情况 水解蛋白注射液为水解物酪蛋白和乳蛋白与山梨醇的灭菌溶液， 主要用于手术严重创伤、大面积烧伤引起的严重氨基酸缺乏，以及各 种疾病引起的低蛋白血症。 三、对公司的影响及风险提示 本次公司分公司获得《药品再注册批准通知书》，将有利于上述 药品恢复正常生产和销售，但不会对公司近期经营业绩产生重大影响。 公司将严格按照要求开展相关后续工作，实现该产品上市销售。由于 药品的生产、销售受国家政策、市场环境等因素影响，具有一定的不 确定性，敬请广大投资者谨慎决策，注意投资风险。 特此公告。 ...

Group 1 - The company has approved the liquidation and deregistration of the Nanjing New Industry Medical Investment Fund Partnership, which will distribute the remaining assets according to the partners' paid-in capital ratio [1] - The fund has obtained the registration notice from the Nanjing Yuhuatai District Administrative Service Management Office, completing the deregistration process [1] - The fund will no longer be included in the company's consolidated financial statements [1] Group 2 - The liquidation of the fund will not adversely affect the company's overall business development or profitability, and there is no harm to the interests of the company and all shareholders [2]

本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、清算注销暨关联交易概述 金陵药业股份有限公司（以下简称"公司"）分别于 2025 年 1 月 一次临时股东大会，审议通过了《关于南京新工医疗产业投资基金合 伙企业（有限合伙）拟清算注销暨关联交易的议案》，同意对南京新 工医疗产业投资基金合伙企业（有限合伙）（以下简称"基金"）进 行清算注销，并按基金合伙人实缴出资比例分配基金剩余财产。同时， 股东大会授权经理层办理与本次基金拟清算注销相关的具体事宜。具 体内容详见公司于 2025 年 1 月 21 日在《中国证券报》《证券时报》 《上海证券报》和巨潮资讯网披露的《关于南京新工医疗产业投资基 金合伙企业（有限合伙）拟清算注销暨关联交易的公告》 （公告编号： 二、清算注销进展情况 近日，基金取得了南京市雨花台区政务服务管理办公室出具的 《登记通知书》（（320101142005）登字〔2025〕第 08140025 号）， 准予基金进行注销登记。至此，基金清算注销的工商登记手续已办理 完毕，不再纳入公司合并报表范围。 证券代码：000919 证券简称：金陵药业 公 ...

一、清算注销暨关联交易概述 证券代码：000919 证券简称：金陵药业 公告编号：2025-056 金陵药业股份有限公司 关于南京新工医疗产业投资基金合伙企业（有限合伙）拟 清算注销暨关联交易的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 三、对公司的影响 本次基金清算注销事项不会对公司整体业务发展及盈利水平产 生不利影响，不存在损害公司及全体股东利益的情形。 四、备查文件 1、《登记通知书》（（320101142005）登字〔2025〕第 08140025 号） 特此公告。 金陵药业股份有限公司董事会 2025 年 8 月 15 日 金陵药业股份有限公司（以下简称"公司"）分别于 2025 年 1 月 17 日、2025 年 2 月 7 日召开第九届董事会第十五次会议和 2025 年第 一次临时股东大会，审议通过了《关于南京新工医疗产业投资基金合 伙企业（有限合伙）拟清算注销暨关联交易的议案》，同意对南京新 工医疗产业投资基金合伙企业（有限合伙）（以下简称"基金"）进 行清算注销，并按基金合伙人实缴出资比例分配基金剩余财产。同时， 股东大会授权经 ...

Core Points - The second extraordinary general meeting of shareholders for 2025 was held on August 8, 2025, with no resolutions being rejected [1][2] - The meeting was conducted in compliance with relevant laws and regulations, ensuring the legitimacy of the proceedings and participants [3][17] Group 1: Meeting Details - The meeting took place at the company's headquarters in Nanjing, combining on-site and online voting methods [3][4] - A total of 200 shareholders attended, representing 302,220,749 shares, which is 48.4554% of the total voting shares [4][5] Group 2: Voting Results - The first resolution regarding the repurchase and cancellation of restricted stock received 99.8798% approval from attending shareholders [8][9] - The second resolution concerning changes to registered capital and amendments to the Articles of Association was approved with 99.8774% [11][12] - The third resolution for the appointment of additional non-independent directors was passed with 99.6078% support [14][15] Group 3: Legal Opinions - The legal opinion from Jiangsu Taihe Law Firm confirmed that the meeting's procedures and voting results were lawful and valid [17] Group 4: Stock Repurchase Announcement - The company announced a stock repurchase plan involving the cancellation of 178,410 shares due to non-compliance with the incentive plan [22] - The total repurchase cost was 6,075,789 yuan, funded by the company's own resources, resulting in a reduction of registered capital from 623,708,628 yuan to 621,924,528 yuan [22][24]

Group 1 - The company Jinling Pharmaceutical announced the convening of its second extraordinary general meeting of shareholders for 2025 on August 8, 2025 [2] - The meeting approved multiple proposals, including the proposal to add non-independent directors [2]

法律意见书 江苏泰和律师事务所 法律意见书 江苏泰和律师事务所 关于金陵药业股份有限公司 法律意见书 关于金陵药业股份有限公司 法律意见书 致：金陵药业股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》（以下简称"《公 司法》"）、中国证券监督管理委员会《上市公司股东会规则》（以下简称"《股 东会规则》"）等法律、法规、规范性文件和《金陵药业股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，江苏泰和律师事务所（以下简称"本所"） 接受金陵药业股份有限公司（以下简称"公司"）的委托，指派律师（以下称"本 所律师"）出席公司 2025 年第二次临时股东大会（以下简称"本次股东大会" "会议"），并出具本法律意见书。 本所律师根据《股东会规则》第六条的要求，出席了本次股东大会并按照律 师行业公认的业务标准、道德规范和勤勉尽责精神，对与本次股东大会召开有关 的文件和事实进行了核查和验证。 本所律师现就本次股东大会的召集和召开程序、出席会议人员和会议召集人 的资格、会议的表决程序、表决结果的合法性、有效性出具如下法律意见： 一、本次股东大会的召集和召开程序 于提请召开公司 2025 年第二次临 ...